Skip to main content

3D Printing and Excipients Designed for Purpose

Thank you

Thank you for your participation in today's webinar. You will be automatically redirected to our webinar evaluation. We look forward to hearing from you!

Description

As we approach the first anniversary of the launch of the FDA’s Novel Excipient Review Pilot Program, join us for an exciting two-part event focused on excipient innovation. Part two is described below. For information on part one (and registration bundling options) visit our event page: Modernizing Excipient Technology - Need for excipients designed for purpose

Save when you register your team! Contact Courtney Nazareno to take advantage of our "Buy 4 get 1 Free" offer.


Characteristics and Requirements of Excipients Designed Specifically for 3D Printing
Presented by: Anna Worsley

Pharmaceutical 3D printing is a rapidly growing field, with more and more pharmaceutical research groups in academia and industry investing time and resources to investigate its use to personalise medicine. The additive manufacturing technology provides the ability to fabricate small batches of precise structures rapidly, allowing for the personalisation of medication with varying dosage, colour, flavour, shape and drug combinations (polypills). Transitioning 3D printing to the pharmacy will require the development of novel formulations aligning with the high-quality standards demanded and regulated by the pharmaceutical industry. This is leading to new challenges and opportunities in research. This presentation will provide an overview of the different 3D printing technologies and materials that are being used in the field.

3D Printing – The future of Pharmaceutical Manufacturing
Presented by: Korinde van den Heuval

3D printing offers huge potential benefits in pharmaceutical manufacturing, like creating fast and reliable wide dosed dosage forms for clinical use and ability to tailor dose in dosage forms for specific user groups. In order to embrace this new world of opportunities, there is a need for thorough understanding of the powder physics of the materials, processes and techniques involved. Powder bed printing is arguably the best method for pharmaceutical manufacturing.
Powder physics like, flowability, wettability and consolidation of the blend are critical material attributes for powder bed printing and will impact the tablet functionality like hardness, disintegration and friability. Limited information is available on excipient selection in relationship to functionality in the dosage form in literature.
DFE pharma aims to provide a starting point for clinical trial formulation development for both hydrophobic or hydrophilic drug compounds. In this presentation, we will show case the 3D powder bed printing technology by utilizing a base formulation of lactose monohydrate/pregelatinized starch at various print settings. It was found that formulation and print settings have to be in conjunction as they are closely related (van den Heuvel et al).
van den Heuvel et al, Evaluation of lactose based 3D powder bed printed pharmaceutical drug product tablets, powder technology (390), 2021, 97-102

Quality Considerations of 3D Printing of Drug Products: ETT Collaborative Approach for Fostering Innovation
Presented by: Ahmed Zidan

Precision medicine is an emerging healthcare delivery approach that considers variability between patients, such as genetic makeups, in contrast to the current one-size-fits-all approach that are designed to treat the average patient. The White House launched the Precision Medicine Initiative in 2015, starting an endeavor to reshape healthcare delivery. To translate the concept of precision medicine from the bench to practice, advanced manufacturing plays an integral part, including 3D printing of personalized drugs and drug delivery devices, and drug screening platforms. These 3D printed products are highly customized and require robust yet flexible manufacturing systems. This presentation will highlight the current status of the development of regulatory submission and quality control considerations of 3D printed drug products.

3D Printing of Microparticles Using Light: Direct Laser Writing
Presented by: Stephen Hoag

During this presentation we will explore the advantages and limitations of 3D printing using direct laser writing (DLW). We will take a look at how microstructures can be created and loaded with drug using this early-stage technology, as well as the excipient requirements for such a process. In addition, we will discuss what happens once particles are made and how the release rate can be controlled using DLW.

Contributors

  • Dr. Anna Worsley

    Director of Innovation
    FabRx Ltd.

    Anna Worsley is Director of Innovation at FabRx. She joined FabRx in May 2021 as a Senior Formulation Scientist after completing her PhD in Biomaterials for Diabetic Chronic Wounds at The Royal Veterinary College and University College London (UCL), her MSc in Nanotechnology and Regenerative Medicine from UCL, and her BSc in Anatomy and Human Biology from The University of Liverpool. During her PhD, Anna also worked in various start-up companies and obtained a place on the Medtech Superconnector Programme, offering additional funding for project continuation after her PhD. Anna hopes to use her varied experiences to support the advancement of FabRx, both with novel formulations and business growth.

  • Korinde van den Heuvel

    Senior Product Developer
    DFE pharma

    Korinde van den Heuvel is senior product developer at DFE pharma since April 2014. In this role she contributed on multiple OSD projects but currently mainly focusing on 3D printing of pharmaceutical tablets. Prior to working at DFE pharma she worked for 10 years at Synthon in formulation development developing various generic plus OSD forms such as ODT, IR and MR tablets and capsules. Korinde holds a master’s degree of Organic chemistry from the Radboud University in Nijmegen, The Netherlands.

  • Ahmed Zidan, M.S., Ph.D.

    Senior Pharmacologist staff fellow
    Division of Product Quality Research, Office of Pharmaceutical Quality, CDER, FDA

    Dr. Zidan is a senior staff fellow (Pharmacologist) in the CDER/OPQ. Ahmed joined FDA in 2005 and has MS and Ph.D. in pharmaceutical sciences. Dr Zidan leads the 3D printing laboratories and research of Division of Product Quality Research in Office of Pharmaceutical Quality and provides hands-on trainings to reviewers on various topics, including 3D printing technologies, Preformulation, PAT implementation to continuous 3D printing processes, preclinical development and scale up of 3D printed drug products and scaffolds for biomedical applications. Dr. Zidan is the government liaison for complex excipients focus group at USP and is a member of the FDA’s additive manufacturing Group and chaired several international and domestic scientific events. Dr. Zidan is also an editorial board member of several pharmaceutical journals and published over 100 peer-reviewed articles and book chapters.

  • Dr. Stephen Hoag, PhD

    Professor of Pharmaceutical Sciences
    University of Maryland, Baltimore

    Stephen W. Hoag, Ph.D. received his Ph.D. in Pharmaceutics from the University of Minnesota-Twin Cities and a B.S. in Biochemistry from the University of Wisconsin-Madison. Dr. Hoag has been a visiting professor at 3M Pharmaceuticals and Abbott Laboratories. His primary research interests are in the area of solid oral formulations, excipient functionality testing, pediatric formulation taste and texture analysis, tablet coating, coating polymers, tablet press instrumentation, tablet compaction modeling. His research has included studies in formulation and process development of tablets, capsules and gels, formulation of folic acid in multivitamin and mineral supplements, taste and texture analysis of pediatric formulation, polymer science, pigment stability in coating polymers and thermal and rheological analysis of polymers, powder flow and formulation stability.

    Hoag has studied the application of near infrared spectroscopy to the analysis of excipient identification, tablet quality and production monitoring for process analytical technology (PAT) applications. Working with Dr. Larry Augsburger, he has edited a four volume set of books on tablet compaction and capsules. Dr. Hoag is a member of NIPTE (National Institute of Pharmaceutical Technology and Education) Executive Committee and he is an AAPS fellow. In addition, he serves on the International Steering Committee for the Handbook of Pharmaceutical Excipients and he serves on the editorial board of the journal of Pharmaceutical Development Technology.

November 2, 2022
Wed 11:00 AM EDT

Duration 2H 0M

This live web event has ended.

Support Contact